DICOT Stock Overview
Dicot AB (publ) engages in the development of pharmaceutical products in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Dicot AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.25 |
| 52 Week High | kr0.42 |
| 52 Week Low | kr0.096 |
| Beta | 1.5 |
| 1 Month Change | 25.51% |
| 3 Month Change | -7.28% |
| 1 Year Change | 24.87% |
| 3 Year Change | -82.15% |
| 5 Year Change | -94.99% |
| Change since IPO | -97.11% |
Recent News & Updates
Shareholder Returns
| DICOT | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 13.5% | -3.0% | 0.9% |
| 1Y | 24.9% | 60.0% | 10.3% |
Return vs Industry: DICOT underperformed the Swedish Pharmaceuticals industry which returned 60% over the past year.
Return vs Market: DICOT exceeded the Swedish Market which returned 10.3% over the past year.
Price Volatility
| DICOT volatility | |
|---|---|
| DICOT Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DICOT's share price has been volatile over the past 3 months.
Volatility Over Time: DICOT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Elin Trampe | www.dicot.se |
Dicot AB (publ) engages in the development of pharmaceutical products in Sweden. It is developing LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was incorporated in 2015 and is based in Uppsala, Sweden.
Dicot AB (publ) Fundamentals Summary
| DICOT fundamental statistics | |
|---|---|
| Market cap | kr203.16m |
| Earnings (TTM) | -kr44.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs DICOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DICOT income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr44.16m |
| Earnings | -kr44.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DICOT perform over the long term?
See historical performance and comparison